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Summary
Background Combination antiretroviral therapy has substantially increased life-expectancy in people living with 
HIV, but the eﬀ ects of chronic infection on health-related quality of life (HRQoL) are unclear. We aimed to compare 
HRQoL in people with HIV and the general population.
Methods We merged two UK cross-sectional surveys: the ASTRA study, which recruited participants aged 18 years 
or older with HIV from eight outpatient clinics in the UK between Feb 1, 2011, and Dec 31, 2012; and the Health 
Survey for England (HSE) 2011, which measures health and health-related behaviours in individuals living in a 
random sample of private households in England. The ASTRA study has data for 3258 people (response rate 64%) 
and HSE for 8503 people aged 18 years or older (response rate 66%). HRQoL was assessed with the Euroqol 5D 
questionnaire 3 level (EQ-5D-3L) instrument that measures health on ﬁ ve domains, each with three levels. The 
responses are scored on a scale where a value of 1 represents perfect health and a value of 0 represents death, 
known as the utility score. We used multivariable models to compare utility scores between the HIV and general 
population samples with adjustment for several sociodemographic factors.
Findings 3151 (97%) of 3258 of participants in ASTRA and 7424 (87%) of 8503 participants in HSE had complete 
EQ-5D-3L data. The EQ-5D-3L utility score was lower for people with HIV compared with that in the general 
population (marginal eﬀ ect in utility score adjusted for age, and sex/sexuality –0·11; 95% CI –0·13 to –0·10; p<0·0001). 
HRQoL was lower for people with HIV for all EQ-5D-3L domains, particularly for anxiety/depression. The diﬀ erence 
in utility score was signiﬁ cant after adjustment for several additional sociodemographic variables (ethnic origin, 
education, having children, and smoking status) and was apparent across all CD4 cell count, antiretroviral therapy, 
and viral load strata, but was greatest for those people diagnosed with HIV in earlier calendar periods. Reduction in 
HRQoL with age was not greater in people with HIV than in the general population (pinteraction>0·05).
Interpretation People living with HIV have signiﬁ cantly lower HRQoL than do the general population, despite 
most HIV positive individuals in this study being virologically and immunologically stable. Although this 
diﬀ erence could in part be due to factors other than HIV, this study provides additional evidence of the loss of 
health that can be avoided through prevention of further HIV infections.
Funding UK National Institute for Health Research.
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Introduction
Evidence suggests that people diagnosed with HIV in 
resource-rich countries have a life expectancy that is 
almost equivalent to that in people without HIV if 
they receive appropriate treatment with combination 
antiretroviral treatment (cART).1 However, despite 
substantial improvements in clinical prognosis, much 
less is known about the health-related quality-of-life 
(HRQoL) of individuals with HIV compared with that in 
the general population.2–4 For example, although evidence 
from studies from the USA show that people with HIV 
have higher rates of depression than do people without 
HIV, the eﬀ ect of HIV status on other domains and 
overall HRQoL is less clear.4 HRQoL is a multidimensional 
concept that incorporates factors such as physical, 
cognitive, emotional, and social functioning. Insight into 
HRQoL is essential to understand the eﬀ ects of HIV as a 
chronic disease. Moreover, when measured with so-
called utility-based instruments, the information can be 
used in economic evaluations to help to generate quality-
adjusted life-years (QALYs), in which one QALY is 
equivalent to a year of perfect health.5
Recent debate has centred around whether people with 
HIV age more quickly as a result of their HIV status6–8—
in other words whether they tend to start having ageing-
related ill-health and disability at a younger age than do 
people without HIV, and whether this diﬀ erence tends to 
widen with older age. The aim of this study was therefore 
two-fold: to assess whether individuals with HIV, 
particularly those who are virologically stable on 
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suppressive treatment, have similar levels of HRQoL 
compared with the general population, after adjustment 
for demographic and socioeconomic variables such as 
age, sex, and smoking status; and to assess whether the 
diﬀ erence in HRQoL between those with HIV and the 
general population increases with older age.
Methods
Study population and procedures
We merged data from two large cross sectional 
questionnaire studies. The ﬁ rst, ASTRA (Antiretrovirals, 
Sexual Transmission Risk and Attitudes study), was 
mainly designed to investigate present patterns of sexual 
behaviour in individuals with diagnosed HIV in the UK. 
Full details regarding the study design are available 
elsewhere.9 Brieﬂ y, the study includes an unselected 
sample of 3258 people with HIV recruited from outpatient 
clinics at eight urban centres in England, between Feb 1, 
2011, and Dec 31, 2012; the response rate was 64%. The 
ASTRA questionnaire was self-completed and available in 
English and French; information about viral load and 
CD4 cell count was extracted from clinical records by 
study personnel. ASTRA includes about 5% of the total 
population with diagnosed HIV in the UK. Participants of 
ASTRA were similar to the UK HIV-diagnosed population 
in terms of age distribution, and the proportion who were 
currently receiving ART.9 However, compared with the UK 
HIV-diagnosed population, ASTRA contains smaller 
proportions of black African people and women, but 
includes a higher percentage of men who have sex with 
men (MSM).9 Ethical approval was granted by the North 
West London REC 2 ethics committee (ref 10/H0720/70) 
and written informed consent was granted.
The second dataset, relating to the general population, 
was derived from the 2011 Health Survey for England 
(HSE).10 The HSE is an annual study designed to measure 
health and health-related behaviours in people living in a 
random sample of private households in England; it 
excludes people who are homeless or living in communal 
buildings such as nursing homes. Participants are 
interviewed at home and later visited by a nurse to collect 
more detailed clinical information. The 2011 survey 
includes interviews for 8503 people aged 18 or older. The 
response rate was 66%; but no information about HIV 
status is recorded. Ethical approval to use the survey data 
was obtained from the Oxford A Research Ethics 
Committee (reference number 10/H0604/56). Oral 
consent was gramted.
HRQoL was deﬁ ned with the generic Euroqol 
questionnaire (EQ-5D-3L) instrument which was used in 
both studies.11 Evidence suggests that this instrument 
exhibits good psychometric properties in terms of its use 
in the measurement of HRQoL in the general population12 
and in people with HIV.13,14 The EQ-5D-3L consists of a 
classiﬁ cation system that measures current health on ﬁ ve 
domains (mobility, self-care, ability to do usual activities, 
pain or discomfort, and anxiety/depression), each with 
three levels (indicating no, some, or extreme problems). 
The (3⁵=243) combinations of categories can be scored, or 
valued, with available country speciﬁ c so-called utility 
algorithms (EQ-5D-3Lutility).15 Utilities are measured on 
interval scales, for which perfect health (no problems on 
all ﬁ ve domains) is equivalent to a value of 1 and death is 
equivalent to a value of 0. These scales are assumed to 
represent the strength of preference for speciﬁ c health-
related outcomes. For example, a health state with a value 
of 0·4 is preferred twice as much as a health state with a 
value of 0·2.
Statistical analysis
Responses were included if participants completed all 
ﬁ ve EQ-5D-3L domain questions and were at least 
18 years of age. Unadjusted diﬀ erences in demographic 
variables and in EQ-5D-3L domains between the HIV 
and general population samples were assessed by χ² tests 
for proportions and Wilcoxon rank sum tests for (non-
normally distributed) continuous variables. Regression 
modelling was used to estimate unadjusted and adjusted 
diﬀ erences in EQ-5D-3Lutility scores compared between the 
HIV sample and the general population sample.
Provisional inspection of the EQ-5D-3Lutility data showed 
they were non-normally distributed, with a spike at 1·0, 
indicating a fairly high proportion of individuals 
reporting perfect health. For this reason, a two-part 
regression model was used for the multivariable analysis. 
This analysis involved ﬁ tting two regression models, the 
results of which are combined to produce a marginal 
eﬀ ect for every independent variable. First, a logistic 
regression was done, in which the dependent variable 
indicated perfect health (yes or no). Generalised linear 
modelling was then done for the data relating to people 
with less than perfect health, with a γ distribution and 
log link because of the left skewed nature of the data; 
proportionately few individuals indicated particularly 
poor HRQoL. The modelling was done with the -tpm- 
routine for STATA v13.1. In this analysis, negative eﬀ ect 
estimates indicate poorer health whereas positive values 
indicate better health.
The choice of which independent variables to include in 
models was restricted for two reasons. First, they needed 
to be common to both the ASTRA and HSE datasets. This 
ruled out for example, variables indicating homelessness, 
hepatitis C status, and recreational drug use (available 
only in ASTRA). Second, the possibility of endogeneity 
was a particular concern. That is, although variables such 
as employment status might inﬂ uence HRQoL, there is a 
plausible loop in causality because HRQoL might also 
aﬀ ect employment status (for example poor health could 
lead to loss of employment). In this sense, such an 
independent variable could be seen as an outcome of, or 
proxy measure for, HRQoL as well as a predictor of it, 
which is problematic in interpretation of the results. 
Therefore employment status, long-term sickness, and 
alcohol use were not judged as potential independent 
For more on the EuroQol Group 
see http://www.euroqol.org/
For more on -tpm- routine see 
http://econpapers.repec.org/
software/bocbocode/s457538.
htm
For the Health Survey for 
England—2011 see
http://www.hscic.gov.uk/
catalogue/PUB09300
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variables in this main analysis. The non-HIV related 
independent variables included: sex/sexuality (men who 
have sex with men [MSM], heterosexual man, or woman); 
age (as a continuous variable); ethnic origin (white or 
non-white); having children (yes or no); maximum 
educational qualiﬁ cation as an indicator of socioeconomic 
status (university degree or higher, A-level, O-level or 
equivalent, less than O-level or equivalent, other, or none); 
and smoking status (never-smoker, ex-smoker, light 
smoker [ten or fewer cigarettes per day], medium smoker 
[11–19 cigarettes per day], heavy smoker [≥20 cigarettes 
per day]).
A series of multivariable models were used to assess the 
eﬀ ect of study sample on HRQoL after adjustment for 
potential confounders. In model 1, only study sample (HIV 
sample compared with general population), age, and sex/
sexuality were included. Model 2 divides the HIV sample 
into two groups (CD4 count greater than 200 cells per μL 
and 200 cells per μL or less); additional analysis (not shown) 
showed that including CD4 count bandings at levels greater 
than 200 cells per μL did not signiﬁ cantly add to the results. 
Adjustment for smoking status and other demographic 
variables (age, ethnic origin, sex/sexuality, having children, 
and maximum educational qualiﬁ cations) were also 
included in model 2. Model 3 was identical to model 2 
except that the HIV sample was categorised in terms of 
treatment status and viral load (on ART with viral load 
≤50 copies per mL; on ART with viral load >50 copies per 
mL; stopped ART; never started ART) rather than by 
CD4 cell count. Model 4 combined the two methods of 
categorisation of the HIV sample, resulting in eight HIV 
categories being compared with the general population 
sample. Model 5 categorised the HIV sample in terms of 
calendar year of diagnosis. Additionally, all ﬁ ve models 
were reanalysed to assess whether the eﬀ ect of age on 
HRQoL was diﬀ erent in the HIV sample compared with 
that in the general population sample. That is, the models 
were rerun including an interaction term between study 
sample (HIV sample compared with general population) 
and age (as a continuous variable).
A potential problem of the use of parametric models 
such as two-part regression models to account for 
imbalances in covariates is that they can be highly 
sensitive to the choice of functional form of the 
regression models (eg, inclusion of higher order terms in 
the logistic regression model). Recent methodological 
work has shown the advantages of matching approaches, 
which aim to create covariate balances between the 
groups being compared. Application of the parametric 
models on a well matched dataset is expected to decrease 
sensitivity to functional form mis-speciﬁ cation.16 Thus, a 
sensitivity analysis was done by rerunning model 1 after 
creation of a one-to-one matched HSE dataset with the 
genetic matching approach described by Sekhon17 (full 
methodological details are available on request). The 
datasets were matched on age, sex, smoking status, 
children, ethnic origin, and educational qualiﬁ cations, 
but not MSM because there were too few MSM in the 
HSE dataset. Model 1 was also reanalysed; ﬁ rst, after 
removal of all MSM and all people who had retired from 
both datasets, and second, after further removal from 
ASTRA, of homeless people, those who had taken any 
recreational drugs in the past 3 months, and everyone 
who had ever been diagnosed with hepatitis C. Finally, 
despite concerns about alcohol use as a predictor of 
HRQoL, the original models 1–5 were rerun with 
adjustment for heavy drinking, deﬁ ned as drinking at 
least 20 units of alcohol per week (yes or no).
Role of the funding source
The funder of the study had no role in the study design 
or conduct, data collection, analysis, or interpretation, 
preparation of the report, or the decision to submit for 
publication. AM had full access to the data and 
responsibility for the decision to submit the report for 
publication.
Results
3151 (96·7%) of 3258 participants of ASTRA had 
complete EQ-5D 3Lutility data and 7424 (87·3%) of 
8503 participants of the HSE. People diagnosed with 
HIV were signiﬁ cantly younger than those in the general 
population sample by roughly 4 years (median 45·2 years, 
IQR 38·9–50·9 vs 49·0 years, 35·0–64·0; p<0·0001). 
People with HIV were also signiﬁ cantly more likely to be 
MSM and heavy smokers and to have higher levels of 
education than people without HIV, but they were less 
likely to be heavy drinkers (table 1). The higher proportion 
of MSM in the ASTRA study than in the HSE was 
unsurprising, but particularly noticeable (table 1). About 
5% (n=170) of ASTRA participants had a CD4 count less 
than 200 cells per μL, 12% had never started ART, and 
overall 75% had a viral load of 50 copies per mL or less 
(table 1).
The unadjusted results show that, despite being 
younger, people with HIV recorded lower levels of health 
compared with the general population on all ﬁ ve 
EQ-5D-3L domains (table 2). The anxiety/depression 
domain was the most markedly reduced, with 24% and 
8% absolute diﬀ erences in the proportions of people who 
reported at least some problems and severe problems in 
the two samples. The mean EQ-5D-3Lutility score was 0·74 
for the HIV sample and 0·82 for the general population 
sample. The unadjusted diﬀ erence in overall EQ-5D-3Lutility 
score was –0·08 (95% CI –0·09 to –0·07).
Model 1 suggests that people with HIV had 
signiﬁ cantly lower EQ-5D-3Lutility scores than those in the 
general population after adjustment for diﬀ erences in 
age and sex/sexuality (–0·11 [95% CI –0·13 to –0·10]; 
table 3). Model 2 shows that adjustment for additional 
factors (ethnic origin, children, education, and smoking 
status) did not explain any of the diﬀ erence in 
EQ-5D-3Lutility between the two samples. Of people with 
HIV, both the group with CD4 counts of 200 cells per 
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mm³ or less and the group with higher CD4 cells counts 
had signiﬁ cantly lower EQ-5D-3Lutility scores than did the 
general population sample (table 3); the diﬀ erence 
between the two CD4 cell count categories was 
statistically signiﬁ cant (–0·04, 95% CI –0·08 to –0·005). 
The results from models 3 and 4 were similar in so 
much that people with HIV consistently recorded lower 
EQ-5D-3Lutility scores than did the general population, 
across ART, viral load, and CD4 cell count categories 
(tables 3 and 4). In particular, the diﬀ erence in 
EQ-5D-3Lutility for people with HIV who were virally 
suppressed with CD4 counts greater than 200 cells 
per μL compared with the general population was –0·11 
(95% CI –0·13 to –0·09). Model 5 clearly indicates that 
calendar year of HIV diagnosis was signiﬁ cantly 
associated with EQ-5D-3Lutility scores, people diagnosed 
more recently had increased HRQoL, even after 
accounting for age and the other covariates (table 5). In 
models 2–5, in addition to HIV status, older age, non-
white ethnic origin, female sex, not having children, 
less education, and present and ex-smoking status were 
also independently associated with reduced EQ-5D-3Lutility 
scores (tables 3–5).
When included, the interaction term between study 
sample (HIV sample compared with general population) 
and age was not statistically signiﬁ cant in any of the 
models (p>0·05 in all instances). In other words, there 
was no evidence that the diﬀ erence in EQ-5D-3Lutility score 
between the two population samples became greater or 
smaller with changing age.
The results form model 1 remained largely unchanged 
when they were rerun with the matched dataset (adjusted 
diﬀ erence between samples: –0·10; 95% CI –0·12 to 
–0·08). The results were also similar after removal of all 
MSM and people who had retired from both datasets and 
after removal of of homeless people, those who had taken 
any recreational drugs in the past 3 months, and people 
who had been ever diagnosed with hepatitis C from 
ASTRA (adjusted diﬀ erence between samples: –0·08; 
95% CI –0·10 to –0·06). Adjustment of models 1–5 for 
heavy drinking had negligible eﬀ ects on the results (data 
not shown).
HIV (n=3151) General population 
(n=7424)
p value*
Mobility problems <0·0001
None 2296 (73%) 5911 (80%)
Some 850 (27%) 1502 (20%)
Severe 5 (<1%) 11 (<1%)
Problems with self-care <0·0001
None 2754 (87%) 7032 (95%)
Some 385 (12%) 367 (5%)
Severe 12 (<1%) 25 (<1%)
Problems performing 
usual activities
<0·0001
None 2128 (68%) 5945 (80%)
Some 936 (30%) 1328 (18%)
Severe 87 (3%) 151 (2%)
Pain/discomfort <0·0001
None 1834 (58%) 4480 (60%)
Some 1091 (35%) 2576 (35%)
Severe 226 (7%) 368 (5%)
Anxiety/depression <0·0001
None 1563 (50%) 5441 (73%)
Some 1268 (40%) 1796 (24%)
Severe 320 (10%) 187 (3%)
Data are n (%). *p values by χ² tests. 
Table 2: EQ-5D-3L health status classiﬁ cations for ASTRA and Health 
Survey for England 
HIV (n=3151) General population 
(n=7424)
p value
Age >50 years 857/3036 (28%) 3478/7424 (47%) <0·0001
Sex/sexuality
Heterosexual male 354/3151 (11%) 3189/7424 (43%) <0·0001
Female 588/3151 (19%) 4177/7424 (56%) <0·0001
Men who have sex with men 2209/3151 (70%) 58/7424 (1%) <0·0001
White 2183/3087 (71%) 6782/7418 (91%) <0·0001
Smoking status
Never 1224/3122 (39%) 3486/7408 (47%) <0·0001
Ex-smoker 918/3122 (29%) 2455/7408 (33%) 0·0002
Light smoker 254/3051 (8%) 530/7408 (7%) 0·038
Medium smoker 339/3051 (11%) 610/7408 (8%) <0·0001
Heavy smoker 316/3051 (10%) 318/7408 (4%) <0·0001
Heavy drinker 321/3123 (10%) 1366/7305 (19%) <0·0001
Long term sick 374/3083 (12%) 237/7233 (3%) <0·0001
Children* 837/3132 (27%) 2145/7424 (29%) 0·024
Education
No qualiﬁ cations 350/3079 (11%) 1586/7417 (21%) <0·0001
O levels or higher 696/3079 (23%) 1564/7417 (21%) 0·085
A levels or higher 612/3079 (20%) 1468/7417 (20%) 0·92
Degree or higher 1288/3079 (42%) 1833/7417 (25%) <0·0001
Employment
Full-time 1507/3083 (49%) 3812/7233 (53%) 0·0004
Part-time 293/3083 (10%) 699/7233 (10%) 0·80
Retired 183/3083 (6%) 1946/7233 (27%) <0·0001
Homeless 33/3095 (1%) ·· ··
Recreational drugs† 1222/3122 (39%) ·· ··
Ever had hepatitis C 424/3151 (13%) ·· ··
CD4 count ≤200 cells per μL 164/3114 (5%) ·· ··
CD4 count >200 cells per μL 2950/3114 (95%) ·· ··
On ART viral load ≤50 copies per mL 2312/3080 (75%) ·· ··
On ART viral load >50 copies per mL 346/3080 (11%) ·· ··
Never started ART 358/3080 (12%) ·· ··
Stopped ART 64/3080 (2%) ·· ··
Data are n (%). All p values relate to χ² tests. Denominators may diﬀ er from sample size because of missing values. At 
least 20 units of alcohol per week. *Health Survey for England records whether people aged younger than 16 years are 
in the household rather than being a parent. †Proportion taking recreational drugs of any type in the past 3 months. 
ART=antiretroviral treatment.
Table 1: ASTRA and Health Survey for England sample demographics 
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Discussion
To our knowledge, this is the largest cross-sectional study 
to compare a standardised measure of HRQoL in people 
living with HIV in the era of ART directly with the general 
population, in a setting with universal access to health 
care, with the ability to simultaneously adjust for multiple 
potential confounders (panel).4 Several multivariable 
models were constructed with diﬀ erent categorisations of 
HIV status, but they consistently showed that people 
diagnosed with HIV had reduced HRQoL compared with 
the general population, across all ART, CD4, and viral load 
categories. In particular, the diﬀ erence was apparent even 
in people who were virally suppressed on ART. Although 
anxiety/depression levels were the most noticeably 
aﬀ ected, all ﬁ ve EQ-5D-3L domains were reduced 
suggesting that HIV infection continues to have systemic 
health implications. This eﬀ ect was greatest in those 
people diagnosed for the longest time (model 5). Despite 
 Model 1 Model 2 Model 3
ME 95% CI; p value ME 95% CI; p value ME 95% CI; p value
HIV status
General popu lation (base) ·· ·· ·· ·· ·· ··
HIV+ –0·11 –0·13 to –0·10; <0·0001 ·· ·· ·· ··
HIV+, CD4 count ≤200 cells per μL ·· ·· –0·15 –0·19 to –0·11; <0·0001 ·· ··
HIV+, CD4 count >200 cells per μL ·· ·· –0·10 –0·12 to –0·08; <0·0001 ·· ··
HIV+, on ART, VL ≤50 copies per mL ·· ·· ·· ·· –0·11 –0·13 to –0·09; <0·0001
HIV+, on ART, VL >50 copies per mL ·· ·· ·· ·· –0·12 –0·15 to –0·09; <0·0001
HIV+, stopped ART ·· ·· ·· ·· –0·14 –0·20 to –0•07;  <0·0001
HIV+, never started ART ·· ·· ·· ·· –0·05 –0·08 to –0·02; 0·0017
Age –0·004 –0·004 to –0·004; <0·0001 –0·003 –0·003 to –0·002; <0·0001 –0·003 –0·003 to –0·002; 0·0037
Sex/sexuality
Male hetero sexual (base) ·· ·· ·· ·· ·· ··
Female –0·03 –0·04 to –0·02; <0·0001 –0·03 –0·05 to –0·02; <0·0001 –0·03 –0·04 to –0·02; <0·0001
MSM –0·008 –0·03 to 0·01; 0·41 0·002 –0·03 to 0·02; 0·84 –0·005 –0·03 to 0·02; 0·65
Ethnic origin
Non-white (base) ·· ·· ·· ·· ·· ··
White ·· ·· 0·02 0·003 to 0·04; 0·02 0·02 0·005 to 0·04; 0·01
Children
No (base) ·· ·· ·· ·· ·· ··
Yes ·· ·· 0·03 0·02 to 0·04; <0·0001 0·03 0·02 to 0·04; <0·0001
Smoking status
Never (base) ·· ·· ·· ·· ·· ··
Ex-smoker ·· ·· –0·03 –0·04 to –0·01; <0·0001 –0·03 –0·04 to –0·01; <0·0001
Light smoker ·· ·· –0·04 –0·06 to –0·02; <0·0001 –0·04 –0·06 to –0·02; <0·0001
Medium smoker ·· ·· –0·06 –0·08 to –0·05; <0·0001 –0·06 –0·08 to –0·05; <0·0001
Heavy smoker ·· ·· –0·12 –0·14 to –0·10; <0·0001 –0·12 –0·14 to –0·10; <0·0001
Max qualiﬁ cation
None (base) ·· ·· ·· ·· ·· ··
O level ·· ·· 0·06 0·04 to 0·07; <0·0001 0·06 0·04 to 0·07; <0·0001
A level ·· ·· 0·08 0·07 to 0·10; <0·0001 0·08 0·07 to 0·10; <0·0001
Degree or higher ·· ·· 0·12 0·10 to 0·13; <0·0001 0·12 0·10 to 0·13; <0·0001
Other ·· ·· 0·09 0·07 to 0·11; <0·0001 0·09 0·07 to 0·11; <0·0001
Model
Number of obser vations 10 078 ·· 9855 ·· 9839 ··
Logit ·· ·· ·· ·· ·· ··
Constant –1·53 ·· –1·00 ·· –0·99 ··
GLM (log link) ·· ·· ·· ·· ·· ··
Constant –1·54 ·· –1·19 ·· –1·17 ··
Log pseudo likelihood –6595 ·· –6326 ·· –6315 ··
For all factors, each category is compared to the base category. Negative utility values indicate poorer health whereas positive values indicate improved health. ME=marginal eﬀ ect; change in the utility score 
associated with a change in each of the independent variables. ART=antiretroviral treatment. VL=viral load. GLM=generalised linear model.
Table 3: Models 1–3—multivariable analysis of factors associated with health-related quality-of-life
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the overall impact of HIV, we did not ﬁ nd any evidence 
that the diﬀ erence in HRQoL between those people living 
with HIV and the general population sample was greater 
with older age.
These results can be used to quantify the average loss 
in HRQoL resulting from each newly diagnosed person 
with HIV. For example, with the results from model 1, 
and supposing that life expectancy is for 40 years after 
HIV diagnosis but is (conservatively) unaﬀ ected by it, the 
loss is equivalent 4·4 (undiscounted) years of perfect 
health, or QALYs, per infection. This loss would reduce 
to 2 QALYs if the aﬀ ect of infection was assumed to be 
–0·05, which was the utility reduction for people infected 
between 2010–12 in model 5.
The multivariable analyses showed that in addition to 
HIV status, factors such as non-white (compared with 
white) ethnic origin and female (compared with 
heterosexual male) sex were also independently associated 
with reduced EQ-5D-3Lutility scores. Thus, these 
demographic groups seem to be among the most 
disadvantaged in terms of present levels of health.
The major strengths of this study are that it contains a 
large number of people with HIV in England (>3000, 
about 5% of all diagnosed patients in the UK), both 
studies were contemporaneous, had satisfactory response 
rates, are reasonably representative of the populations of 
interest, and some major potential confounding factors 
such smoking status were adjusted for. Additionally, 
recruitment in both studies took place in a way that 
would not be expected to select strongly for healthier 
participants; ASTRA recruited from hospital clinics and 
participants of HSE were visited in their homes. Further, 
the studies were done in a setting with universally free 
health care, which is likely to reduce the potential for 
confounding by access to health care. Although non-
response rates were similar in each study, bias would be 
introduced if characteristics of non-responders diﬀ ered 
between the studies. For example, if people with poorer 
physical or mental health were less likely to participate in 
HSE, but this was not the case for participation in 
ASTRA, the HSE study population would contain people 
with greater than average levels of health, and the 
diﬀ erences in HRQoL we noted would be overestimates.
The proportion of people who participated in HSE or 
ASTRA who did not complete all ﬁ ve EQ-5D-3L questions, 
and therefore were excluded from the analyses, was 9% 
greater in the HSE sample. Although so-called response 
fatigue could partly explain this diﬀ erence, because HSE 
participants were required to answer a much longer set of 
questions, whether this introduces bias into the analysis or 
the plausible eﬀ ect of it is unknown. For example, perhaps 
people in HSE who had no ill health elected not to 
complete the instrument, meaning the diﬀ erences in 
HRQoL we report are an underestimate. Conversely, 
people in HSE might have been too ill to complete all the 
questions, which would lead to an overestimation of 
diﬀ erences.
The diﬀ erences in health that we report might not be a 
direct result of HIV infection, but could result in part 
from other unmeasured diﬀ erences between the ASTRA 
and HSE populations. Moreover, we did not make 
multivariable adjustments for all potentially confounding 
factors, such as homelessness and hepatitis C status, 
because the information was not available in both 
datasets. However, adjustments for major potential 
ME 95% CI; p value
HIV status
General population (base category) ·· ··
HIV+, on ART, VL ≤50 copies per mL, CD4 count ≤200 cells per μL –0·13 –0·19 to –0·07; <0·0001
HIV+, on ART, VL ≤50 copies per mL, CD4 count >200 cells per μL –0·11 –0·13 to –0·09; <0·0001
HIV+, on ART, VL >50 copies per mL, CD4 count ≤200 cells per μL –0·15 –0·21 to –0·09; <0·0001
HIV+, on ART, VL >50 copies per mL, CD4 count >200 cells per μL –0·11 –0·14 to –0·08; <0·0001
HIV+, stopped ART, CD4 count ≤200 cells per μL –0·18 –0·34 to –0·02; 0·022
HIV+, stopped ART, CD4 count >200 cells per μL –0·13 –0·20 to –0·06; 0·0001
HIV+, never started ART, CD4 count ≤200 cells per μL –0·17 –0·30 to –0·03; 0·015
HIV+, never started ART, CD4 count >200 cells per μL –0·04 –0·07 to –0·01; 0·014
Age –0·003 –0·003 to –0·002; 
<0·0001
Sex/sexuality
Male hetero sexual (base) ·· ··
Female –0·03 –0·05 to –0·02; <0·0001
MSM –0·007 –0·03 to 0·02; 0·56
Ethnic origin
Non-white (base) ·· ··
White 0·02 0·004 to 0·04; 0·015
Children
No (base) ·· ··
Yes 0·03 0·02 to 0·04; <0·0001
Smoking status
Never (base) ·· ··
Ex-smoker –0·03 –0·04 to –0·01; <0·0001
Light smoker –0·04 –0·06 to –0·02; <0·0001
Medium smoker –0·06 –0·08 to –0·05; <0·0001
Heavy smoker –0·12 –0·14 to –0·10; <0·0001
Max qualiﬁ cation
None (base) ·· ··
O level 0·06 0·04 to 0·07; <0·0001
A level 0·08 0·07 to 0·10; <0·0001
Degree or higher 0·12 0·10 to 0·13; <0·0001
Other 0·09 0·07 to 0·11; <0·0001
Model
Number of obser vations 9830 ··
Logit ·· ··
Constant –1·00 ··
GLM (log link) ·· ··
Constant –1·18 ··
Log pseudo likelihood –6307 ··
For all factors, each category is compared to the base category. Negative utility values indicate poorer health whereas 
positive values indicate improved health. ME=marginal eﬀ ect; change in the utility score associated with a change in 
each of the independent variables. ART=antiretroviral treatment. VL=viral load. GLM=generalised linear model.
Table 4: Model 4—multivariable analysis of factors associated with health-related quality-of-life
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confounders such as smoking status and social class (as 
measured by level of education), did not attenuate the 
diﬀ erence in HRQoL between the two cross-sectional 
samples, neither did the use of a matched dataset to 
more fully account for diﬀ erences in most observable 
factors. Further analyses are planned with the ASTRA 
sample linked to clinical level data to investigate the 
eﬀ ects of health-related factors such as previous non-
AIDS and AIDS clinical conditions on HRQoL.
The HSE study included a much lower proportion of 
self-reported MSM, who could for example, have diﬀ erent 
levels of psychological wellbeing compared with other 
men.18 Although this factor alone does not explain the 
diﬀ erence in HRQoL between the two population 
samples because removal of all MSM from both samples 
had little eﬀ ect on the results, the extent to which this 
issue confounds the results is unknown. Studies 
comparing HRQoL between HIV-positive and HIV-
negative MSM would shed light on this issue.
Although HSE does not record HIV status, and is 
therefore likely to include people with HIV, we do not 
deem this to detract from the analysis because HSE 
participants were randomly selected and the prevalence 
of HIV infection in the UK is about 1·5 in 1000, meaning 
that HSE is predicted to contain around ten people with 
HIV.
Several recent studies have measured HRQoL in 
people living with HIV,19–21 but few have directly compared 
levels with those recorded in the general population.2,8,22 
A large US study6 of data from 2009 showed that the 
prevalence of depression was three-times higher in 
people with HIV than in the general population. 
Adjustments were made for several potentially 
confounding factors such as age, sex, and educational 
levels, but not for factors such as smoking and stage of 
HIV infection. However, because a third of people living 
with HIV in the USA are thought not to be accessing 
regular care,23 the potential for confounding by access to 
health care is greater in the USA study.
Previous studies have consistently concluded that 
individuals diagnosed with HIV have high levels of 
depression.4,24,25 Our study noted higher levels of self-
reported anxiety/depression in the HIV sample than in 
the general population, even after adjustment for several 
other confounding variables such as smoking status and 
immunological or virological status. This high prevalence 
of depression among people living with HIV could be 
because of a range of factors including those related to 
living with a chronic disease, social circumstances, 
relationship issues, stigma, or the eﬀ ects of speciﬁ c 
drugs. The extent to which elevated anxiety/depression 
evident in MSM living with HIV are also apparent in 
HIV-negative MSM is unknown. Some evidence suggests 
that a high prevalence of depression exists independently 
of HIV status in groups such as MSM.18 Whatever the 
underlying drivers of the diﬀ erence in anxiety/depression 
between those with and without HIV, the ﬁ ndings further 
emphasise the importance in identiﬁ cation of those 
people with HIV who have psychological symptoms and 
in oﬀ ering appropriate care. The results suggest this is 
particularly true for people who were diagnosed in the 
earlier period of the epidemic and have been living with 
HIV for many years (model 5, table 5); possibly in part 
ME 95% CI; p value
HIV status
General population (base 
category)
·· ··
HIV+, diagnosed 1980–84 –0·26 –0·36 to –0·16; <0·0001
HIV+, diagnosed 1985–89 –0·19 –0·23 to –0·15; <0·0001
HIV+, diagnosed 1990–94 –0·17 –0·20 to –0·14; <0·0001
HIV+, diagnosed 1995–99 –0·13 –0·15 to –0·10; <0·0001
HIV+, diagnosed 2000–04 –0·11 –0·14 to –0·09; <0·0001
HIV+, diagnosed 2005–09 –0·07 –0·09 to –0·04; <0·0001
HIV+, diagnosed 2010–12 –0·05 –0·08 to –0·02; <0·0001
Age –0·003 –0·003 to –0·002; 0·008
Sex/sexuality
Male hetero sexual (base) ·· ··
Female –0·03 –0·04 to –0·02; <0·0001
MSM 0·01 –0·01 to 0·03; 0·42
Ethnic origin
Non-white (base) ·· ··
White 0·02 0·006 to 0·04; 0·008
Children
No (base) ·· ··
Yes 0·03 0·02 to 0·04; <0·0001
Smoking status
Never (base) ·· ··
Ex-smoker –0·02 –0·03 to –0·01; 0·0001
Light smoker –0·04 –0·06 to –0·02; 0•0001
Medium smoker –0·06 –0·08 to –0·05; <0·0001
Heavy smoker –0·12 –0·14 to –0·10; <0·0001
Max qualiﬁ cation
None (base) ·· ··
O level 0·06 0·05 to 0·08; <0·0001
A level 0·09 0·07 to 0·10; <0·0001
Degree or higher 0·12 0·10 to 0·14; <0·0001
Other 0·09 0·07 to 0·11; <0·0001
Model
Number of obser vations 9870 ··
Logit ·· ··
Constant –0·91 ··
GLM (log link) ·· ··
Constant –1·13 ··
Log pseudo likelihood –6039 ··
For all factors, each category is compared to the ‘base’ category’. Negative utility 
values indicate poorer health whereas positive values indicate improved health. 
ME=marginal eﬀ ect; change in the utility score associated with a change in each 
of the independent variables. ART=antiretroviral treatment. VL=viral load. 
GLM=generalised linear model.
Table 5: Model 5—multivariable analysis of factors associated with 
health-related quality-of-life
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Systematic review
In June, 2014, we searched PubMed, Medline, and Embase for studies that compared the 
health-related quality-of-life (HRQoL) of people with diagnosed HIV with the general 
population. We did not apply any language or date restrictions, and used combinations of 
the search terms ‘‘HIV’’, ‘‘AIDS’’, ‘‘quality-of-life’’, and ‘‘population’’. Studies including 
people with haemophilia were excluded. The review identiﬁ ed several studies have 
compared HRQoL between these two population groups,2–4 one of which was a recent 
study.4 All seem to suggest that HIV signiﬁ cantly aﬀ ects HRQoL on several health domains, 
but those measuring anxiety/depression seemed to be the most frequently reduced.
Interpretation
Our study is the largest study of its kind in the UK and in a population with universal 
access to health care. We found that people living with HIV have reduced HRQoL 
compared with the general population, and that this diﬀ erence was apparent even for 
those people with HIV who were on ART and virologically suppressed. Unlike previous 
studies, we assessed whether the diﬀ erence in HRQoL between the two population 
samples diﬀ ers with older age, and we identiﬁ ed no evidence to suggest this is the case. 
Although access to modern cART seems to be associated with life expectancy that is 
almost equivalent to people who are uninfected, HIV continues to aﬀ ect morbidity. Our 
ﬁ ndings provides evidence of the loss of health that can be avoided through prevention 
of further HIV infections.
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